Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Comparative Effectiveness Research | 17 | 2020 | 714 | 2.920 |
Why?
|
Cost-Benefit Analysis | 46 | 2020 | 5536 | 2.900 |
Why?
|
Insurance Coverage | 16 | 2018 | 1946 | 2.390 |
Why?
|
Drug Costs | 12 | 2020 | 1195 | 1.970 |
Why?
|
Prescription Drugs | 5 | 2018 | 635 | 1.630 |
Why?
|
Health Maintenance Organizations | 17 | 2007 | 657 | 1.460 |
Why?
|
Health Care Costs | 14 | 2018 | 3239 | 1.390 |
Why?
|
Models, Economic | 10 | 2020 | 719 | 1.360 |
Why?
|
Delivery of Health Care | 13 | 2019 | 5367 | 1.350 |
Why?
|
Physician Incentive Plans | 6 | 2008 | 165 | 1.050 |
Why?
|
Insurance, Health | 11 | 2018 | 2517 | 1.040 |
Why?
|
Drug Industry | 4 | 2019 | 791 | 0.960 |
Why?
|
Orphan Drug Production | 2 | 2018 | 48 | 0.960 |
Why?
|
Physician-Patient Relations | 14 | 2013 | 3269 | 0.950 |
Why?
|
Decision Making | 14 | 2019 | 3953 | 0.900 |
Why?
|
Costs and Cost Analysis | 7 | 2019 | 1667 | 0.890 |
Why?
|
Conflict of Interest | 4 | 2017 | 556 | 0.860 |
Why?
|
Evidence-Based Medicine | 11 | 2020 | 3706 | 0.770 |
Why?
|
Reimbursement Mechanisms | 4 | 2017 | 670 | 0.770 |
Why?
|
Anti-Obesity Agents | 2 | 2023 | 240 | 0.760 |
Why?
|
Ethics, Medical | 8 | 2012 | 785 | 0.760 |
Why?
|
Policy Making | 6 | 2020 | 546 | 0.740 |
Why?
|
Health Policy | 8 | 2019 | 2697 | 0.740 |
Why?
|
Academies and Institutes | 4 | 2019 | 326 | 0.730 |
Why?
|
Pregnenediones | 1 | 2020 | 29 | 0.700 |
Why?
|
Benzyl Compounds | 1 | 2020 | 19 | 0.700 |
Why?
|
Technology Assessment, Biomedical | 4 | 2018 | 312 | 0.680 |
Why?
|
Rare Diseases | 2 | 2018 | 631 | 0.670 |
Why?
|
United States | 61 | 2019 | 73039 | 0.660 |
Why?
|
Hypercholesterolemia | 2 | 2017 | 1145 | 0.650 |
Why?
|
Critical Pathways | 7 | 2001 | 476 | 0.650 |
Why?
|
Oligonucleotides | 2 | 2020 | 563 | 0.650 |
Why?
|
Antidepressive Agents | 5 | 2020 | 2913 | 0.640 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 57 | 0.630 |
Why?
|
Insurance, Pharmaceutical Services | 3 | 2018 | 348 | 0.630 |
Why?
|
Dystrophin | 1 | 2020 | 284 | 0.630 |
Why?
|
Policy | 2 | 2019 | 513 | 0.630 |
Why?
|
Azetidines | 1 | 2020 | 152 | 0.620 |
Why?
|
Proprotein Convertases | 2 | 2016 | 95 | 0.610 |
Why?
|
Complement C1 Inhibitor Protein | 1 | 2019 | 97 | 0.610 |
Why?
|
Chest Pain | 8 | 2011 | 1101 | 0.590 |
Why?
|
Managed Care Programs | 8 | 2007 | 939 | 0.590 |
Why?
|
Angioedemas, Hereditary | 1 | 2019 | 91 | 0.590 |
Why?
|
Economics, Pharmaceutical | 1 | 2018 | 88 | 0.580 |
Why?
|
Quality of Health Care | 17 | 2014 | 4310 | 0.580 |
Why?
|
Drug Compounding | 1 | 2018 | 242 | 0.570 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2016 | 1188 | 0.570 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 256 | 0.570 |
Why?
|
Off-Label Use | 3 | 2017 | 185 | 0.560 |
Why?
|
Oligonucleotides, Antisense | 1 | 2020 | 462 | 0.560 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2020 | 271 | 0.560 |
Why?
|
Medicine | 6 | 2014 | 945 | 0.550 |
Why?
|
Prescription Fees | 1 | 2018 | 153 | 0.550 |
Why?
|
Anti-Asthmatic Agents | 2 | 2019 | 577 | 0.540 |
Why?
|
Prealbumin | 1 | 2019 | 259 | 0.540 |
Why?
|
Muscular Atrophy, Spinal | 1 | 2019 | 260 | 0.530 |
Why?
|
Financial Support | 1 | 2017 | 116 | 0.530 |
Why?
|
Triage | 6 | 2011 | 997 | 0.520 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2020 | 10397 | 0.520 |
Why?
|
Capitation Fee | 3 | 2002 | 115 | 0.520 |
Why?
|
Health Services Research | 8 | 2010 | 1815 | 0.520 |
Why?
|
Amyloid Neuropathies, Familial | 1 | 2019 | 180 | 0.500 |
Why?
|
Health Care Reform | 3 | 2014 | 1256 | 0.500 |
Why?
|
Social Responsibility | 3 | 2014 | 382 | 0.490 |
Why?
|
Analgesia | 1 | 2020 | 460 | 0.490 |
Why?
|
Decision Support Techniques | 6 | 2019 | 2008 | 0.480 |
Why?
|
State Medicine | 2 | 2007 | 219 | 0.480 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2015 | 388 | 0.470 |
Why?
|
Humans | 153 | 2023 | 768171 | 0.470 |
Why?
|
Opiate Substitution Treatment | 1 | 2019 | 452 | 0.470 |
Why?
|
Continuity of Patient Care | 5 | 2003 | 1078 | 0.470 |
Why?
|
Health Care Rationing | 3 | 2016 | 435 | 0.470 |
Why?
|
Administrative Personnel | 1 | 2015 | 185 | 0.460 |
Why?
|
Narcotic Antagonists | 1 | 2019 | 591 | 0.460 |
Why?
|
Tetrazoles | 3 | 2017 | 923 | 0.450 |
Why?
|
Uridine Monophosphate | 1 | 2014 | 67 | 0.450 |
Why?
|
Gatekeeping | 3 | 2003 | 49 | 0.450 |
Why?
|
Ketamine | 1 | 2020 | 527 | 0.440 |
Why?
|
Physicians | 7 | 2014 | 4598 | 0.430 |
Why?
|
Preventive Health Services | 2 | 2016 | 570 | 0.420 |
Why?
|
Legislation, Drug | 2 | 2017 | 216 | 0.410 |
Why?
|
Blood Pressure Determination | 1 | 2016 | 646 | 0.410 |
Why?
|
Ethylene Glycols | 1 | 2014 | 198 | 0.400 |
Why?
|
Tetrahydronaphthalenes | 1 | 2012 | 85 | 0.400 |
Why?
|
Hepatitis C | 3 | 2017 | 1595 | 0.400 |
Why?
|
Drug Approval | 3 | 2019 | 821 | 0.390 |
Why?
|
Affect | 1 | 2020 | 1495 | 0.390 |
Why?
|
Specialization | 3 | 2002 | 779 | 0.390 |
Why?
|
Anticholesteremic Agents | 2 | 2016 | 972 | 0.390 |
Why?
|
Data Collection | 8 | 2014 | 3326 | 0.390 |
Why?
|
Quality-Adjusted Life Years | 11 | 2019 | 1741 | 0.390 |
Why?
|
Hypnotics and Sedatives | 1 | 2020 | 1191 | 0.390 |
Why?
|
Cost Savings | 2 | 2014 | 904 | 0.390 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2014 | 296 | 0.380 |
Why?
|
Resource Allocation | 4 | 2016 | 354 | 0.380 |
Why?
|
Clinical Trials as Topic | 6 | 2020 | 8052 | 0.380 |
Why?
|
Patient Participation | 2 | 2020 | 1447 | 0.380 |
Why?
|
Treatment Outcome | 28 | 2020 | 65379 | 0.380 |
Why?
|
Diffusion of Innovation | 4 | 2011 | 724 | 0.370 |
Why?
|
Biomedical Research | 4 | 2020 | 3463 | 0.370 |
Why?
|
Pharmaceutical Preparations | 2 | 2017 | 1088 | 0.370 |
Why?
|
Family Practice | 5 | 2001 | 509 | 0.360 |
Why?
|
Practice Guidelines as Topic | 5 | 2017 | 7454 | 0.360 |
Why?
|
Fluorine Radioisotopes | 1 | 2014 | 425 | 0.360 |
Why?
|
Professional Autonomy | 1 | 2012 | 172 | 0.360 |
Why?
|
Vertebroplasty | 1 | 2011 | 78 | 0.360 |
Why?
|
Unnecessary Procedures | 1 | 2014 | 412 | 0.350 |
Why?
|
Biological Products | 2 | 2019 | 947 | 0.350 |
Why?
|
Physicians, Family | 4 | 2003 | 349 | 0.350 |
Why?
|
Patient Satisfaction | 8 | 2013 | 3490 | 0.340 |
Why?
|
Primary Health Care | 11 | 2007 | 4746 | 0.340 |
Why?
|
Decision Making, Organizational | 1 | 2010 | 136 | 0.340 |
Why?
|
Medical Oncology | 2 | 2012 | 2346 | 0.340 |
Why?
|
Health Priorities | 2 | 2016 | 380 | 0.340 |
Why?
|
Hepatitis C, Chronic | 2 | 2016 | 1032 | 0.330 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3428 | 0.330 |
Why?
|
Employee Incentive Plans | 1 | 2009 | 15 | 0.330 |
Why?
|
Glucocorticoids | 1 | 2019 | 2167 | 0.330 |
Why?
|
Disabled Persons | 1 | 2019 | 1210 | 0.330 |
Why?
|
Macular Edema | 1 | 2013 | 387 | 0.330 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2016 | 1065 | 0.320 |
Why?
|
Coronary Angiography | 2 | 2011 | 4541 | 0.320 |
Why?
|
Thrombophlebitis | 5 | 1999 | 289 | 0.320 |
Why?
|
Antiviral Agents | 4 | 2016 | 3072 | 0.310 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2013 | 878 | 0.310 |
Why?
|
Attitude to Health | 5 | 2013 | 2025 | 0.310 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2726 | 0.300 |
Why?
|
Internal Medicine | 4 | 2003 | 1064 | 0.300 |
Why?
|
Clinical Competence | 4 | 2011 | 4858 | 0.300 |
Why?
|
Methylphenidate | 1 | 2012 | 480 | 0.300 |
Why?
|
Motivation | 4 | 2009 | 2020 | 0.300 |
Why?
|
Health Expenditures | 7 | 2018 | 2389 | 0.300 |
Why?
|
Aniline Compounds | 1 | 2014 | 1094 | 0.300 |
Why?
|
Disclosure | 3 | 2017 | 755 | 0.300 |
Why?
|
Financing, Personal | 2 | 2013 | 310 | 0.290 |
Why?
|
Medical Records Systems, Computerized | 2 | 2005 | 1196 | 0.290 |
Why?
|
Pulmonary Artery | 1 | 2016 | 1946 | 0.290 |
Why?
|
Referral and Consultation | 6 | 2003 | 3620 | 0.290 |
Why?
|
Alzheimer Disease | 3 | 2014 | 8759 | 0.290 |
Why?
|
Obesity | 2 | 2023 | 13091 | 0.290 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 2 | 2013 | 3729 | 0.280 |
Why?
|
Drug Labeling | 1 | 2009 | 250 | 0.280 |
Why?
|
Colonography, Computed Tomographic | 1 | 2008 | 170 | 0.280 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4206 | 0.280 |
Why?
|
Ethical Review | 1 | 2006 | 27 | 0.270 |
Why?
|
Biopharmaceutics | 1 | 2006 | 23 | 0.270 |
Why?
|
Research Design | 6 | 2016 | 6209 | 0.260 |
Why?
|
Health Benefit Plans, Employee | 1 | 2009 | 332 | 0.260 |
Why?
|
Health Services Accessibility | 5 | 2018 | 5520 | 0.260 |
Why?
|
Chronic Disease | 5 | 2018 | 9384 | 0.260 |
Why?
|
Antibodies, Monoclonal | 5 | 2018 | 9262 | 0.260 |
Why?
|
United States Food and Drug Administration | 5 | 2019 | 1673 | 0.260 |
Why?
|
Investments | 1 | 2007 | 149 | 0.260 |
Why?
|
Bariatric Surgery | 1 | 2016 | 1001 | 0.250 |
Why?
|
Emergency Service, Hospital | 10 | 2011 | 7951 | 0.250 |
Why?
|
Attitude | 2 | 2001 | 772 | 0.250 |
Why?
|
Efficiency, Organizational | 3 | 2009 | 697 | 0.250 |
Why?
|
Guidelines as Topic | 2 | 2009 | 1397 | 0.250 |
Why?
|
New England | 4 | 2013 | 1058 | 0.240 |
Why?
|
Attitude of Health Personnel | 7 | 2015 | 3929 | 0.240 |
Why?
|
Medicare | 6 | 2017 | 6809 | 0.240 |
Why?
|
Heart Failure | 6 | 2017 | 11879 | 0.240 |
Why?
|
Ambulatory Care | 5 | 2005 | 2783 | 0.230 |
Why?
|
Biotechnology | 1 | 2006 | 283 | 0.230 |
Why?
|
Sulfonamides | 1 | 2014 | 1982 | 0.230 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2188 | 0.230 |
Why?
|
Biomedical Technology | 1 | 2006 | 210 | 0.230 |
Why?
|
Diabetic Retinopathy | 1 | 2013 | 1300 | 0.220 |
Why?
|
Massachusetts | 10 | 2019 | 8890 | 0.220 |
Why?
|
Central Nervous System Stimulants | 1 | 2012 | 1168 | 0.220 |
Why?
|
Trust | 3 | 2006 | 532 | 0.220 |
Why?
|
Group Practice | 3 | 2012 | 149 | 0.220 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2013 | 1489 | 0.220 |
Why?
|
Angiogenesis Inhibitors | 1 | 2013 | 2057 | 0.220 |
Why?
|
Men | 1 | 2003 | 64 | 0.220 |
Why?
|
Personnel Turnover | 1 | 2003 | 89 | 0.210 |
Why?
|
Patient Care | 2 | 2012 | 629 | 0.210 |
Why?
|
Sex Education | 1 | 2003 | 94 | 0.210 |
Why?
|
Self Report | 2 | 2014 | 3773 | 0.210 |
Why?
|
Coitus | 1 | 2003 | 132 | 0.210 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3837 | 0.210 |
Why?
|
Asthma | 2 | 2019 | 6291 | 0.210 |
Why?
|
Quality of Life | 5 | 2019 | 13490 | 0.200 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2013 | 3517 | 0.200 |
Why?
|
Decision Trees | 3 | 1996 | 508 | 0.190 |
Why?
|
Database Management Systems | 1 | 2003 | 263 | 0.190 |
Why?
|
Quality Indicators, Health Care | 1 | 2011 | 1805 | 0.180 |
Why?
|
Politics | 2 | 2014 | 822 | 0.180 |
Why?
|
Family Planning Services | 1 | 2003 | 279 | 0.180 |
Why?
|
Psoriasis | 2 | 2018 | 926 | 0.170 |
Why?
|
Drug Prescriptions | 1 | 2009 | 1668 | 0.170 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3533 | 0.160 |
Why?
|
Insurance Claim Review | 2 | 2003 | 744 | 0.160 |
Why?
|
Hospitals, University | 1 | 2001 | 570 | 0.160 |
Why?
|
Patient Advocacy | 4 | 2012 | 362 | 0.160 |
Why?
|
Budgets | 2 | 2013 | 232 | 0.160 |
Why?
|
Florida | 2 | 2011 | 417 | 0.160 |
Why?
|
Immunotherapy, Adoptive | 2 | 2019 | 1512 | 0.150 |
Why?
|
Coercion | 2 | 2009 | 68 | 0.150 |
Why?
|
California | 2 | 2019 | 1438 | 0.150 |
Why?
|
Internship and Residency | 4 | 2005 | 5953 | 0.150 |
Why?
|
Patient Acceptance of Health Care | 3 | 2003 | 3231 | 0.150 |
Why?
|
Hospitalists | 2 | 2000 | 298 | 0.150 |
Why?
|
Administration, Intranasal | 1 | 2020 | 485 | 0.150 |
Why?
|
Pharmacopoeias as Topic | 1 | 2017 | 16 | 0.150 |
Why?
|
Watchful Waiting | 2 | 2013 | 492 | 0.150 |
Why?
|
Clinical Protocols | 2 | 1995 | 1443 | 0.140 |
Why?
|
England | 3 | 2016 | 533 | 0.140 |
Why?
|
Medicaid | 3 | 2017 | 2840 | 0.140 |
Why?
|
Health Behavior | 1 | 2009 | 2650 | 0.140 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 1999 | 345 | 0.140 |
Why?
|
Surgical Procedures, Operative | 3 | 2011 | 1933 | 0.140 |
Why?
|
Communication | 5 | 2013 | 3905 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 20762 | 0.140 |
Why?
|
Life Style | 1 | 2009 | 3932 | 0.140 |
Why?
|
Patient Admission | 5 | 2000 | 1365 | 0.140 |
Why?
|
Aerosols | 1 | 2020 | 634 | 0.140 |
Why?
|
Polyvinyl Chloride | 2 | 1994 | 32 | 0.140 |
Why?
|
Boston | 12 | 2006 | 9374 | 0.140 |
Why?
|
Biphenyl Compounds | 3 | 2017 | 1026 | 0.140 |
Why?
|
Methadone | 1 | 2019 | 317 | 0.140 |
Why?
|
Naltrexone | 1 | 2019 | 319 | 0.130 |
Why?
|
United States Agency for Healthcare Research and Quality | 1 | 2016 | 86 | 0.130 |
Why?
|
Arthritis, Rheumatoid | 1 | 2012 | 3781 | 0.130 |
Why?
|
Adult | 31 | 2020 | 223646 | 0.130 |
Why?
|
Education, Medical, Continuing | 1 | 2001 | 829 | 0.130 |
Why?
|
Administration, Inhalation | 1 | 2019 | 1169 | 0.130 |
Why?
|
Antigens, CD19 | 1 | 2019 | 446 | 0.130 |
Why?
|
Drug Combinations | 3 | 2017 | 2089 | 0.130 |
Why?
|
Male | 46 | 2020 | 364731 | 0.120 |
Why?
|
Delayed-Action Preparations | 1 | 2019 | 969 | 0.120 |
Why?
|
Conscious Sedation | 1 | 2020 | 534 | 0.120 |
Why?
|
Prednisone | 1 | 2020 | 1567 | 0.120 |
Why?
|
Middle Aged | 35 | 2020 | 223487 | 0.120 |
Why?
|
Patient Readmission | 5 | 2000 | 3288 | 0.120 |
Why?
|
Education, Medical, Graduate | 2 | 2005 | 2420 | 0.120 |
Why?
|
Dermatologic Agents | 1 | 2018 | 313 | 0.120 |
Why?
|
Patients | 1 | 2001 | 908 | 0.120 |
Why?
|
Female | 44 | 2020 | 397187 | 0.120 |
Why?
|
Consensus Development Conferences as Topic | 1 | 1995 | 169 | 0.120 |
Why?
|
Home Care Services, Hospital-Based | 3 | 1999 | 44 | 0.120 |
Why?
|
Exons | 1 | 2020 | 2394 | 0.110 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 6316 | 0.110 |
Why?
|
Serine Endopeptidases | 2 | 2016 | 1027 | 0.110 |
Why?
|
Length of Stay | 8 | 2001 | 6498 | 0.110 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 15662 | 0.110 |
Why?
|
Lorazepam | 1 | 1994 | 155 | 0.110 |
Why?
|
Venous Thrombosis | 2 | 1999 | 1321 | 0.100 |
Why?
|
Diethylhexyl Phthalate | 1 | 1993 | 86 | 0.100 |
Why?
|
Professional Corporations | 1 | 1992 | 9 | 0.100 |
Why?
|
Diagnosis-Related Groups | 1 | 1994 | 445 | 0.100 |
Why?
|
Arthroplasty, Replacement, Knee | 2 | 2001 | 1389 | 0.100 |
Why?
|
Interprofessional Relations | 1 | 1999 | 997 | 0.100 |
Why?
|
Treatment Failure | 2 | 2014 | 2661 | 0.100 |
Why?
|
Informed Consent | 2 | 2009 | 1010 | 0.100 |
Why?
|
Hospital Information Systems | 1 | 1995 | 395 | 0.100 |
Why?
|
Aptamers, Nucleotide | 1 | 2013 | 163 | 0.100 |
Why?
|
Fees, Medical | 2 | 2003 | 111 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 2019 | 945 | 0.100 |
Why?
|
Drugs, Generic | 1 | 2017 | 455 | 0.100 |
Why?
|
Advisory Committees | 1 | 2016 | 796 | 0.100 |
Why?
|
Minocycline | 1 | 1993 | 170 | 0.100 |
Why?
|
Freedom | 1 | 2012 | 69 | 0.100 |
Why?
|
Eosinophils | 1 | 2016 | 952 | 0.100 |
Why?
|
Gastroenterology | 1 | 1998 | 593 | 0.100 |
Why?
|
Cerebral Arterial Diseases | 1 | 2011 | 82 | 0.090 |
Why?
|
Health Promotion | 1 | 2003 | 2210 | 0.090 |
Why?
|
Societies, Medical | 2 | 2014 | 3968 | 0.090 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2016 | 407 | 0.090 |
Why?
|
Buprenorphine | 1 | 2019 | 667 | 0.090 |
Why?
|
Colorado | 1 | 2011 | 167 | 0.090 |
Why?
|
Rifampin | 1 | 1993 | 352 | 0.090 |
Why?
|
Coronary Artery Disease | 1 | 2010 | 6568 | 0.090 |
Why?
|
Anticarcinogenic Agents | 1 | 2012 | 251 | 0.090 |
Why?
|
Hospitals, Teaching | 6 | 2000 | 1157 | 0.090 |
Why?
|
Depression | 2 | 2001 | 8230 | 0.090 |
Why?
|
Aged | 28 | 2020 | 171502 | 0.090 |
Why?
|
Echocardiography, Stress | 1 | 2011 | 138 | 0.090 |
Why?
|
Analysis of Variance | 6 | 2001 | 6229 | 0.090 |
Why?
|
RNA Interference | 1 | 2019 | 2832 | 0.090 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 662 | 0.090 |
Why?
|
Multiple Myeloma | 2 | 2018 | 5196 | 0.090 |
Why?
|
Myocardial Infarction | 7 | 1999 | 11519 | 0.080 |
Why?
|
Medical Staff, Hospital | 1 | 1994 | 603 | 0.080 |
Why?
|
Risk-Taking | 1 | 1995 | 1023 | 0.080 |
Why?
|
Severity of Illness Index | 5 | 2019 | 15949 | 0.080 |
Why?
|
Patient Compliance | 2 | 2001 | 2697 | 0.080 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1515 | 0.080 |
Why?
|
Cholesterol, LDL | 2 | 2016 | 2403 | 0.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 1560 | 0.080 |
Why?
|
Reimbursement, Incentive | 2 | 2007 | 541 | 0.080 |
Why?
|
Markov Chains | 3 | 2018 | 979 | 0.080 |
Why?
|
Paternalism | 1 | 2009 | 49 | 0.080 |
Why?
|
Acute Disease | 9 | 1999 | 7243 | 0.080 |
Why?
|
Public Opinion | 1 | 2013 | 486 | 0.080 |
Why?
|
European Union | 1 | 2010 | 158 | 0.080 |
Why?
|
Ethics, Clinical | 1 | 2009 | 101 | 0.080 |
Why?
|
Algorithms | 3 | 1995 | 14164 | 0.080 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2009 | 105 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2018 | 1596 | 0.080 |
Why?
|
Organizational Culture | 1 | 1992 | 513 | 0.080 |
Why?
|
Age Factors | 3 | 2019 | 18415 | 0.080 |
Why?
|
Electroconvulsive Therapy | 1 | 2013 | 504 | 0.070 |
Why?
|
Insurance Carriers | 1 | 2010 | 159 | 0.070 |
Why?
|
Administration, Oral | 1 | 2016 | 4034 | 0.070 |
Why?
|
Organizational Policy | 2 | 2008 | 435 | 0.070 |
Why?
|
Mandatory Programs | 1 | 2008 | 86 | 0.070 |
Why?
|
Wales | 1 | 2007 | 87 | 0.070 |
Why?
|
Child Health Services | 1 | 2013 | 645 | 0.070 |
Why?
|
Patient Rights | 1 | 2008 | 126 | 0.070 |
Why?
|
Evaluation Studies as Topic | 3 | 2003 | 1627 | 0.070 |
Why?
|
Health Care Surveys | 3 | 2007 | 2434 | 0.070 |
Why?
|
Critical Care | 1 | 2020 | 2715 | 0.070 |
Why?
|
Focus Groups | 3 | 2013 | 1460 | 0.070 |
Why?
|
Emergency Medical Services | 1 | 1998 | 1947 | 0.070 |
Why?
|
Critical Illness | 1 | 2020 | 2755 | 0.070 |
Why?
|
Quality Assurance, Health Care | 2 | 2007 | 2176 | 0.070 |
Why?
|
Child | 6 | 2019 | 80917 | 0.070 |
Why?
|
Standard of Care | 1 | 2011 | 568 | 0.070 |
Why?
|
Macular Degeneration | 1 | 2014 | 1015 | 0.070 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2237 | 0.070 |
Why?
|
Social Values | 1 | 2007 | 224 | 0.070 |
Why?
|
Young Adult | 5 | 2020 | 60066 | 0.070 |
Why?
|
Parenting | 1 | 2012 | 708 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2020 | 3800 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2535 | 0.060 |
Why?
|
Incidental Findings | 1 | 2011 | 698 | 0.060 |
Why?
|
Stroke Volume | 2 | 2017 | 5622 | 0.060 |
Why?
|
Physician's Role | 2 | 2004 | 925 | 0.060 |
Why?
|
Qualitative Research | 2 | 2016 | 3140 | 0.060 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 1140 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1951 | 0.060 |
Why?
|
Los Angeles | 1 | 2006 | 245 | 0.060 |
Why?
|
Psychiatry | 1 | 1998 | 1716 | 0.060 |
Why?
|
Monte Carlo Method | 1 | 2011 | 1259 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2013 | 21207 | 0.060 |
Why?
|
Health Services | 2 | 2001 | 755 | 0.060 |
Why?
|
Fee-for-Service Plans | 2 | 2001 | 713 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 1960 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 1 | 2013 | 3740 | 0.060 |
Why?
|
Drug Design | 1 | 2010 | 1046 | 0.060 |
Why?
|
Leadership | 1 | 1994 | 1397 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2005 | 642 | 0.060 |
Why?
|
Research | 2 | 2007 | 1979 | 0.060 |
Why?
|
Patient Transfer | 3 | 2000 | 792 | 0.060 |
Why?
|
Forecasting | 1 | 2013 | 2945 | 0.060 |
Why?
|
Congresses as Topic | 1 | 2009 | 812 | 0.060 |
Why?
|
Neoplasm Staging | 3 | 2013 | 11244 | 0.060 |
Why?
|
Drug Incompatibility | 2 | 1993 | 11 | 0.060 |
Why?
|
Drug Stability | 2 | 1994 | 292 | 0.050 |
Why?
|
Choice Behavior | 1 | 2009 | 848 | 0.050 |
Why?
|
Solutions | 2 | 1994 | 409 | 0.050 |
Why?
|
Patient-Centered Care | 1 | 2013 | 1444 | 0.050 |
Why?
|
Time Factors | 7 | 2010 | 40220 | 0.050 |
Why?
|
Education, Medical | 3 | 2000 | 1742 | 0.050 |
Why?
|
Group Practice, Prepaid | 1 | 2001 | 15 | 0.050 |
Why?
|
Government Regulation | 1 | 2006 | 525 | 0.050 |
Why?
|
Anecdotes as Topic | 1 | 2002 | 56 | 0.050 |
Why?
|
Ethics, Institutional | 1 | 2001 | 38 | 0.050 |
Why?
|
Utilization Review | 1 | 2003 | 381 | 0.050 |
Why?
|
Adolescent Health Services | 1 | 2003 | 220 | 0.050 |
Why?
|
Pain Measurement | 1 | 2011 | 3583 | 0.050 |
Why?
|
Curriculum | 3 | 2003 | 3782 | 0.050 |
Why?
|
Computers, Handheld | 1 | 2003 | 211 | 0.050 |
Why?
|
Allergy and Immunology | 1 | 2002 | 175 | 0.040 |
Why?
|
Odds Ratio | 6 | 1999 | 9669 | 0.040 |
Why?
|
Cohort Studies | 10 | 2019 | 41753 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2005 | 643 | 0.040 |
Why?
|
Anticoagulants | 1 | 2016 | 4850 | 0.040 |
Why?
|
Occupational Therapy | 1 | 2001 | 141 | 0.040 |
Why?
|
Amyloid beta-Peptides | 1 | 2014 | 3914 | 0.040 |
Why?
|
Prevalence | 2 | 2012 | 15869 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2003 | 12077 | 0.040 |
Why?
|
Convalescence | 1 | 2000 | 107 | 0.040 |
Why?
|
Intellectual Property | 1 | 2019 | 32 | 0.040 |
Why?
|
Child, Preschool | 2 | 2013 | 42669 | 0.040 |
Why?
|
Stents | 1 | 2011 | 3197 | 0.040 |
Why?
|
Fees and Charges | 2 | 2013 | 189 | 0.040 |
Why?
|
Office Visits | 1 | 2003 | 595 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 14729 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2018 | 9419 | 0.040 |
Why?
|
Prostatic Neoplasms | 2 | 2013 | 11101 | 0.040 |
Why?
|
Hospital Units | 1 | 2000 | 142 | 0.040 |
Why?
|
Electrocardiography | 2 | 2011 | 6412 | 0.040 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2018 | 42 | 0.040 |
Why?
|
Regression Analysis | 2 | 2001 | 6340 | 0.040 |
Why?
|
Hospital Bed Capacity, 500 and over | 2 | 1998 | 113 | 0.040 |
Why?
|
Phosphodiesterase 4 Inhibitors | 1 | 2018 | 37 | 0.040 |
Why?
|
Ethics Committees | 1 | 1998 | 51 | 0.040 |
Why?
|
Goals | 1 | 2004 | 717 | 0.040 |
Why?
|
Adolescent | 4 | 2020 | 89169 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1986 | 2204 | 0.040 |
Why?
|
Physical Therapy Modalities | 1 | 2001 | 533 | 0.040 |
Why?
|
Educational Measurement | 1 | 2005 | 1260 | 0.040 |
Why?
|
Logistic Models | 4 | 2007 | 13290 | 0.040 |
Why?
|
Appointments and Schedules | 1 | 2002 | 443 | 0.040 |
Why?
|
Depressive Disorder | 2 | 2001 | 3721 | 0.040 |
Why?
|
Prospective Payment System | 1 | 1998 | 134 | 0.040 |
Why?
|
Pilot Projects | 1 | 2011 | 8741 | 0.040 |
Why?
|
Perception | 1 | 2014 | 1209 | 0.040 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 5176 | 0.040 |
Why?
|
Medication Adherence | 1 | 2009 | 2187 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15453 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6669 | 0.030 |
Why?
|
Interleukin-23 | 1 | 2018 | 202 | 0.030 |
Why?
|
Random Allocation | 1 | 2001 | 2395 | 0.030 |
Why?
|
Thoracic Surgical Procedures | 1 | 2001 | 350 | 0.030 |
Why?
|
Patient Preference | 2 | 2016 | 946 | 0.030 |
Why?
|
Needs Assessment | 1 | 2003 | 1141 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11878 | 0.030 |
Why?
|
Patient Selection | 3 | 2012 | 4260 | 0.030 |
Why?
|
Patient Discharge | 3 | 2000 | 3479 | 0.030 |
Why?
|
Lisinopril | 1 | 2016 | 60 | 0.030 |
Why?
|
Interleukin-12 | 1 | 2018 | 577 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2019 | 13677 | 0.030 |
Why?
|
Probability | 1 | 2001 | 2479 | 0.030 |
Why?
|
Treatment Refusal | 1 | 1999 | 433 | 0.030 |
Why?
|
Colectomy | 1 | 2001 | 696 | 0.030 |
Why?
|
Hysterectomy | 1 | 2001 | 863 | 0.030 |
Why?
|
Empathy | 1 | 2000 | 474 | 0.030 |
Why?
|
Interinstitutional Relations | 1 | 1996 | 235 | 0.030 |
Why?
|
Planning Techniques | 1 | 1995 | 81 | 0.030 |
Why?
|
Veins | 1 | 1999 | 769 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2018 | 646 | 0.030 |
Why?
|
Total Quality Management | 1 | 1996 | 265 | 0.030 |
Why?
|
Angioedema | 1 | 2016 | 184 | 0.030 |
Why?
|
Skilled Nursing Facilities | 1 | 1999 | 405 | 0.030 |
Why?
|
Time and Motion Studies | 1 | 1995 | 143 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2018 | 6847 | 0.030 |
Why?
|
Fluorenes | 1 | 2016 | 160 | 0.030 |
Why?
|
Methods | 1 | 1995 | 1066 | 0.030 |
Why?
|
Brachytherapy | 2 | 2013 | 1220 | 0.030 |
Why?
|
Republic of Korea | 1 | 2016 | 591 | 0.030 |
Why?
|
Drug Packaging | 1 | 1994 | 44 | 0.030 |
Why?
|
Dyspepsia | 1 | 1995 | 116 | 0.030 |
Why?
|
Forms and Records Control | 1 | 1995 | 158 | 0.030 |
Why?
|
Drug Storage | 1 | 1994 | 52 | 0.030 |
Why?
|
Polyenes | 1 | 1994 | 68 | 0.030 |
Why?
|
Leg | 1 | 1999 | 1088 | 0.030 |
Why?
|
Withholding Treatment | 1 | 1998 | 620 | 0.030 |
Why?
|
Prostatectomy | 2 | 2013 | 1786 | 0.030 |
Why?
|
Prospective Studies | 6 | 1999 | 54924 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7852 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 3436 | 0.030 |
Why?
|
Group Processes | 1 | 1995 | 227 | 0.030 |
Why?
|
Cross-Sectional Studies | 4 | 2014 | 26379 | 0.030 |
Why?
|
Isotonic Solutions | 1 | 1994 | 119 | 0.030 |
Why?
|
Retrospective Studies | 9 | 2003 | 81760 | 0.030 |
Why?
|
Polysorbates | 1 | 1993 | 46 | 0.030 |
Why?
|
Plastics | 1 | 1994 | 119 | 0.030 |
Why?
|
Digital Rectal Examination | 1 | 2013 | 42 | 0.030 |
Why?
|
Patient Education as Topic | 3 | 2001 | 2337 | 0.030 |
Why?
|
Infusions, Parenteral | 1 | 1993 | 396 | 0.030 |
Why?
|
Low Back Pain | 1 | 2001 | 990 | 0.030 |
Why?
|
Survival Analysis | 2 | 2019 | 10099 | 0.030 |
Why?
|
Health Resources | 1 | 1999 | 950 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18349 | 0.030 |
Why?
|
Systems Integration | 1 | 1995 | 430 | 0.030 |
Why?
|
Risk | 3 | 2010 | 9613 | 0.030 |
Why?
|
Interleukin-17 | 1 | 2018 | 924 | 0.030 |
Why?
|
Workload | 1 | 1998 | 849 | 0.030 |
Why?
|
Chemistry, Pharmaceutical | 1 | 1993 | 274 | 0.020 |
Why?
|
Prostate-Specific Antigen | 2 | 2013 | 2463 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1250 | 0.020 |
Why?
|
Medical Records | 4 | 1999 | 1410 | 0.020 |
Why?
|
Angina Pectoris | 1 | 1996 | 957 | 0.020 |
Why?
|
Heparin | 2 | 1996 | 1636 | 0.020 |
Why?
|
Coronary Artery Bypass | 1 | 2001 | 2191 | 0.020 |
Why?
|
Sodium Chloride | 1 | 1994 | 584 | 0.020 |
Why?
|
Home Care Services | 1 | 1998 | 659 | 0.020 |
Why?
|
Uncertainty | 1 | 2016 | 769 | 0.020 |
Why?
|
Models, Theoretical | 2 | 2000 | 3573 | 0.020 |
Why?
|
Delphi Technique | 1 | 1995 | 890 | 0.020 |
Why?
|
Injections | 1 | 1994 | 841 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1008 | 0.020 |
Why?
|
Malpractice | 1 | 1995 | 561 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 1993 | 1379 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2016 | 864 | 0.020 |
Why?
|
Registries | 1 | 2006 | 8375 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2107 | 0.020 |
Why?
|
Communication Barriers | 1 | 2013 | 419 | 0.020 |
Why?
|
Models, Statistical | 2 | 1995 | 5107 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 2568 | 0.020 |
Why?
|
Health Status Indicators | 1 | 1995 | 969 | 0.020 |
Why?
|
Animals | 2 | 2012 | 169285 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1993 | 1535 | 0.020 |
Why?
|
Health Surveys | 1 | 1999 | 4057 | 0.020 |
Why?
|
Program Evaluation | 3 | 2007 | 2507 | 0.020 |
Why?
|
Documentation | 1 | 1995 | 917 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2008 | 6975 | 0.020 |
Why?
|
Hepacivirus | 1 | 2016 | 1344 | 0.020 |
Why?
|
South Australia | 2 | 1998 | 27 | 0.020 |
Why?
|
Inpatients | 1 | 2000 | 2566 | 0.020 |
Why?
|
Confidence Intervals | 1 | 1994 | 2923 | 0.020 |
Why?
|
Hospitalization | 2 | 2016 | 10840 | 0.020 |
Why?
|
Risk Factors | 7 | 2013 | 74944 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2016 | 1886 | 0.020 |
Why?
|
Warfarin | 1 | 2016 | 1493 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2018 | 4355 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2830 | 0.020 |
Why?
|
Neoplasms | 2 | 2012 | 22371 | 0.020 |
Why?
|
Ethanol | 1 | 1993 | 1331 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 1996 | 2430 | 0.020 |
Why?
|
Viral Load | 1 | 2016 | 3396 | 0.020 |
Why?
|
Temperature | 1 | 1993 | 2234 | 0.020 |
Why?
|
Ultrasonography | 2 | 1999 | 6004 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8509 | 0.020 |
Why?
|
Age Distribution | 1 | 2012 | 2873 | 0.020 |
Why?
|
Sinusitis | 1 | 1995 | 997 | 0.020 |
Why?
|
Observer Variation | 1 | 1992 | 2621 | 0.020 |
Why?
|
Health Planning | 1 | 2007 | 233 | 0.020 |
Why?
|
Hospitals, Urban | 2 | 2000 | 497 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2013 | 1514 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 1995 | 20225 | 0.020 |
Why?
|
Mice | 1 | 2012 | 82049 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2010 | 905 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2003 | 5891 | 0.020 |
Why?
|
Interviews as Topic | 2 | 2007 | 2741 | 0.020 |
Why?
|
Disease Progression | 2 | 2013 | 13668 | 0.010 |
Why?
|
Comorbidity | 1 | 1999 | 10590 | 0.010 |
Why?
|
Patient Care Team | 1 | 1995 | 2523 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 1999 | 4055 | 0.010 |
Why?
|
Sex Factors | 2 | 1996 | 10632 | 0.010 |
Why?
|
Prognosis | 2 | 2018 | 30009 | 0.010 |
Why?
|
Hypertension | 1 | 2003 | 8616 | 0.010 |
Why?
|
Consumer Advocacy | 1 | 2004 | 83 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 2 | 1999 | 1243 | 0.010 |
Why?
|
Health Status | 1 | 2016 | 4091 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5341 | 0.010 |
Why?
|
Aged, 80 and over | 5 | 2016 | 59626 | 0.010 |
Why?
|
Interdisciplinary Communication | 1 | 2007 | 937 | 0.010 |
Why?
|
Models, Biological | 1 | 2018 | 9497 | 0.010 |
Why?
|
Biopsy | 1 | 2013 | 6792 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 13045 | 0.010 |
Why?
|
Hospital Costs | 2 | 1999 | 957 | 0.010 |
Why?
|
Atherosclerosis | 1 | 2016 | 3433 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 1995 | 13013 | 0.010 |
Why?
|
Organizational Objectives | 1 | 2001 | 426 | 0.010 |
Why?
|
Fibrinolytic Agents | 2 | 1999 | 2080 | 0.010 |
Why?
|
Minnesota | 1 | 1999 | 339 | 0.010 |
Why?
|
Exercise Test | 2 | 1997 | 2186 | 0.010 |
Why?
|
Sertraline | 1 | 2000 | 209 | 0.010 |
Why?
|
New South Wales | 1 | 1998 | 69 | 0.010 |
Why?
|
Hospital Charges | 1 | 2000 | 347 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2000 | 15833 | 0.010 |
Why?
|
Aspirin | 2 | 1999 | 3135 | 0.010 |
Why?
|
Confidentiality | 1 | 2001 | 607 | 0.010 |
Why?
|
Androgens | 2 | 1954 | 1281 | 0.010 |
Why?
|
Ancillary Services, Hospital | 1 | 1996 | 23 | 0.010 |
Why?
|
Institutional Management Teams | 1 | 1996 | 31 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 24318 | 0.010 |
Why?
|
Job Satisfaction | 1 | 2000 | 548 | 0.010 |
Why?
|
Personnel, Hospital | 1 | 1998 | 285 | 0.010 |
Why?
|
Software Design | 1 | 1996 | 173 | 0.010 |
Why?
|
Emergency Treatment | 1 | 1999 | 497 | 0.010 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 1996 | 234 | 0.010 |
Why?
|
Partial Thromboplastin Time | 1 | 1996 | 204 | 0.010 |
Why?
|
Australia | 1 | 1999 | 1265 | 0.010 |
Why?
|
Serum Albumin | 1 | 1998 | 677 | 0.010 |
Why?
|
Benchmarking | 1 | 2001 | 1057 | 0.010 |
Why?
|
Coronary Care Units | 1 | 1995 | 235 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 1998 | 1737 | 0.010 |
Why?
|
Dihydrotestosterone | 1 | 1954 | 195 | 0.010 |
Why?
|
Medical History Taking | 1 | 1996 | 779 | 0.010 |
Why?
|
Aftercare | 1 | 1998 | 916 | 0.010 |
Why?
|
Follow-Up Studies | 3 | 1999 | 39354 | 0.010 |
Why?
|
Diagnostic Tests, Routine | 1 | 1996 | 789 | 0.010 |
Why?
|
Physical Examination | 1 | 1996 | 1263 | 0.010 |
Why?
|
Faculty, Medical | 1 | 1998 | 1226 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2000 | 6029 | 0.010 |
Why?
|
Bayes Theorem | 1 | 1997 | 2359 | 0.010 |
Why?
|
Steroids | 1 | 1954 | 938 | 0.000 |
Why?
|
Feasibility Studies | 1 | 1999 | 5315 | 0.000 |
Why?
|
Myocardial Ischemia | 1 | 1998 | 2138 | 0.000 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 1998 | 2763 | 0.000 |
Why?
|
Mortality | 1 | 1998 | 2911 | 0.000 |
Why?
|
Income | 1 | 1995 | 1878 | 0.000 |
Why?
|
Radiography | 1 | 1996 | 6986 | 0.000 |
Why?
|
Aging | 2 | 1954 | 8743 | 0.000 |
Why?
|
Mass Screening | 1 | 2000 | 5458 | 0.000 |
Why?
|
Lung | 1 | 1996 | 10101 | 0.000 |
Why?
|